Name Address/P.O. Box Postal Code/City Country Contact Person Telephone Fax Email Website Social Media Number of Employees Founded (year) Areas of Activity External Collaborations
›
Formycon AG
›
Fraunhoferstr. 15 82152 Martinsried/Planegg Germany Sabrina Müller +49-89-864-667-100 +49-89-864-667-110 sabrina.mueller@formycon.com www.formycon.com
›
LI Q
› › › › › › ›
› ›
›
›
~170 2012 Biosimilar Development, COVID-19 Drug Development FYB201, Formycon’s Biosimilar Candidate to Lucentis® (ranibizumab), licensed out to Bioeq AG, a joint venture between Strüngmann Group and Polpharma Biologics. Commercialisation of FYB201 by Coherus BioSciences, Inc. in the United States of America, Teva Pharmaceutical Industries Ltd. in Europe and other territories and MS Pharma in Middle East and North Africa. FYB202, Formycon’s Biosimilar Candidate to Stelara® (ustekinumab), developed in a joint venture with Aristo Pharma GmbH, a company owned by the Strüngmann Group. FYB203, Formycon’s Biosimilar Candidate to Eylea® (aflibercept), licensed out to Klinge Biopharma GmbH, a company owned by the Strüngmann Group. FYB207, Formycon’s COVID-19 Drug in development with academic partners Prof. Dr Ulrike Protzer, Chair of Virology, and Prof. Dr Johannes Buchner, Chair of Biotechnology, Technical University of Munich. Licensed out to SCG Cell Therapy Pte Ltd for Asia-Pacific-Region (except Japan).
Who we are: Formycon is an expert company for the development of high-quality biopharmaceuticals, especially biosimilar medicines. The company’s pipeline contains three late-stage biosimilars, one preclinical biosimilar and an innovative COVID-19 drug.
Biosimilars – Medicines for the Future A biosimilar medicine is a biological medicine highly similar to another already approved biological medicine (the ‘reference medicine’). Biosimilars are approved according to the same standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines. Through their proven efficacy, cost efficiency, and high standard of quality, biosimilar medicines are already making a major contribution towards improving patient access to essential medical treatments. Thereby biosimilars help patients around the world and also help to ease the financial strains on the world’s healthcare systems.
What we do: Formycon develops biosimilars for the rapidly growing disease areas of ophthalmology and immunology as well as for other key chronic diseases. Formycon covers all stages of biopharmaceutical development from analytics and cell line development to preclinical and clinical studies, all the way through to the preparation of regulatory submission documents. We develop biosimilar medicines to meet the high standards of the world’s most regulated markets: European Union, United States, Canada, Japan, and Australia.
